Data on several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Virtual Meeting 2020, which will take place from 29 to 31 May 2020.
• Oral presentation #502
Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
Denkert C, Lambertini C, Fasching PA, et al.
Session: Oral Abstract Session / Breast Cancer—Local/Regional/Adjuvant
Speaker: Carsten Denkert
• Poster discussion #516
GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).
Moebus V, Lueck HJ, Ladda E.et al.
Session: Poster Discussion Session / Breast Cancer—Local/Regional/Adjuvant
Speaker: Volker Möbus
• Poster #580
Influence of denosumab on disseminated tumor cells (DTC) in the bone marrow of breast cancer (BC) patients with neoadjuvant treatment: A GeparX translational substudy.
Wimberger P, Blohmer J-U, Krabisch P, et al.
Session: Poster Session / Breast Cancer—Local/Regional/Adjuvant
• Poster #567
Factors associated with axillary conversion after neoadjuvant chemotherapy in initially node positive breast cancer patients: A transSENTINA analysis.
Kolberg HC, Kühn T, Krajewska M, et al.
Session: Poster Session / Breast Cancer - Local/Regional/Adjuvant